Making up the majority of all eukaryotic proteins, glycoproteins have a wide range of important physiological roles, from cell-cell signaling to disease pathogenesis.
Alejandra Manjarrez, PhD | May 16, 2022 | 3 min read
A sugar that’s less abundant in the blood of people with diabetes binds to SARS-CoV-2’s spike protein and disrupts the virus’s ability to fuse with cells.
The Scientist’s Creative Services Team and Bio-Techne | 1 min read
In this webinar, Javier Castillo-Olivares and Matteo Ferrari will discuss what they have learned about COVID-19 through testing patient sera with automated immunoblotting.
The SARS-CoV-2 variant was first detected in January, but its rising prevalence and potential resistance to vaccines has garnered it special attention from the World Health Organization.
Alejandra Manjarrez, PhD | Jun 15, 2021 | 4 min read
Researchers find that surges in COVID-19 case numbers are associated with deletions in the SARS-CoV-2 genome in an antigenic site of the spike protein. Some of these mutations are present in vaccine breakthrough infections or reinfections.
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
Long before Moderna’s and Pfizer’s COVID-19 shots, scientists had been considering the use of genetically encoded vaccines in the fight against infectious diseases, cancer, and more.
The Scientist’s Creative Services Team | 1 min read
Experts will discuss their research on SARS-CoV-2 antibody persistence and immune memory in recovered COVID-19 patients and the implications for protective immunity.
Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.
SARS-CoV-2, the virus that causes COVID-19, taps into human proteases such as furin to enter cells. Temporarily inhibiting those enzymes might stymie infection.
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?